NASAL POLYPS TREATMENT MARKET ANALYSIS

Nasal Polyps Treatment Market, by Drug Class, (Corticosteroids, (Nasal corticosteroids, Fluticasone, Budesonide, Mometasone, Triamcinolone, Others - Beclomethasone, Ciclesonide, etc.), Oral/Injectable Corticosteroids (Prednisone, Combination), Antibiotics, Antihistamines, Interleukin Inhibitors, (Dupilumab, Others (IL 10, IL 25 etc.)), Monoclonal Antibodies, (Mepolizumab, Omalizumab, Others), Others (Aspirin, anticholinergic agent and etc.)), by Route of Administration (Nasal, Oral, Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Aug 2022
Code : CMI2775
Pages :520
Formats :
Excel and PDF
Industry : Pharmaceutical

Nasal Polyps Treatment MarketSize and Trends

Global nasal polyps treatment market is estimated to be valued at US$ 2,992.21 Mn in 2022 and is expected to exhibit a CAGR of 6.9% over the forecast period (2022-2030)

Figure 1: Global Nasal Polyps Treatment Market Share, (%), Analysis, By Drug Class, 2022

Market players are involved in launching of new products for the treatment of nasal polyps. This is expected to drive growth of the global nasal polyps treatment market over the forecast period.

Market players are developing new product and this is expected to drive growth of the global nasal polyps treatment market over the forecast period. For instance, in April 2018, Intersect ENT Inc. a subsidiary of Medtronic, a medical device company, launched a product, SINUVA. SINUVA is non-surgical option used for the treatment of nasal polyps. It reduced sinus obstacle and improves reduced sense of smell. It reduced symptoms of nasal obstacle and congestion for up to 90 days.

Figure 2: Global Nasal Polyps Treatment Market (US$ Bn), by Region, 2022